Meta-analysis results of the SGLT-Is trials for stroke risk with different baseline characteristics across studies, those diabetic populations not at a risk, or those at risk for CKD or CVD are summarized in the Supplementary Appendix (fixed and random effect models, Supplementary Figures S2, S3)
Remarkably, ~5090% reduction of L68Q-hCC staining was observed in five of the treated carriers suggesting that L68Q-hCC is a clinical target for reducing agents
or a p-value ( a )
Dosing Frequency Overview of Common GLP-1 Receptor Agonists Liraglutide Liraglutide treats Type 2 diabetes mellitus (T2DM) as the first daily injectable GLP-1 receptor agonist (GLP-1 RA) (15)(23)
Given the wide use of these drugs, these adverse events, although rare, must be considered by patients thinking about using them for weight loss, said first author Mohit Sodhi, a graduate of UBCs experimental medicine program and fourth year UBC medical student studying the adverse events of commonly prescribed medications
Some of the links below contain affiliate links